🚀 VC round data is live in beta, check it out!
NeuroSense Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for NeuroSense Therapeutics and similar public comparables like Diamyd Medical, Tevogen Bio, Gensight Biologics, Skye Bioscience and more.
NeuroSense Therapeutics Overview
About NeuroSense Therapeutics
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Founded
2017
HQ
Employees
15
Website
Sectors
Financials (LTM)
EV
$24M
NeuroSense Therapeutics Financials
NeuroSense Therapeutics reported last 12-month revenue of $196K.
In the same LTM period, NeuroSense Therapeutics generated had net loss of ($11M).
Revenue (LTM)
NeuroSense Therapeutics P&L
In the most recent fiscal year, NeuroSense Therapeutics reported revenue of — and EBITDA of ($11M).
NeuroSense Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $196K | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($11M) | XXX | XXX | XXX |
| EBIT Margin | (5725%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($11M) | XXX | ($11M) | XXX | XXX | XXX |
| Net Margin | (5743%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
NeuroSense Therapeutics Stock Performance
NeuroSense Therapeutics has current market cap of $24M, and enterprise value of $24M.
Market Cap Evolution
NeuroSense Therapeutics' stock price is $0.73.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $24M | $24M | 0.0% | XXX | XXX | XXX | $-0.33 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNeuroSense Therapeutics Valuation Multiples
NeuroSense Therapeutics trades at 124.6x EV/Revenue multiple, and (2.2x) EV/EBITDA.
EV / Revenue (LTM)
NeuroSense Therapeutics Financial Valuation Multiples
As of April 11, 2026, NeuroSense Therapeutics has market cap of $24M and EV of $24M.
Equity research analysts estimate NeuroSense Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NeuroSense Therapeutics has a P/E ratio of (2.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $24M | XXX | $24M | XXX | XXX | XXX |
| EV (current) | $24M | XXX | $24M | XXX | XXX | XXX |
| EV/Revenue | 124.6x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.2x) | XXX | XXX | XXX |
| EV/EBIT | (2.2x) | XXX | (2.2x) | XXX | XXX | XXX |
| P/E | (2.2x) | XXX | (2.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified NeuroSense Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
NeuroSense Therapeutics Margins & Growth Rates
NeuroSense Therapeutics' revenue in the last 12 month grew by 624%.
NeuroSense Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.
NeuroSense Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 624% | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 12% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2880% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2965% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
NeuroSense Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Diamyd Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Tevogen Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Gensight Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Skye Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Initiator Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NeuroSense Therapeutics M&A Activity
NeuroSense Therapeutics acquired XXX companies to date.
Last acquisition by NeuroSense Therapeutics was on XXXXXXXX, XXXXX. NeuroSense Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by NeuroSense Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNeuroSense Therapeutics Investment Activity
NeuroSense Therapeutics invested in XXX companies to date.
NeuroSense Therapeutics made its latest investment on XXXXXXXX, XXXXX. NeuroSense Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by NeuroSense Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout NeuroSense Therapeutics
| When was NeuroSense Therapeutics founded? | NeuroSense Therapeutics was founded in 2017. |
| Where is NeuroSense Therapeutics headquartered? | NeuroSense Therapeutics is headquartered in Israel. |
| How many employees does NeuroSense Therapeutics have? | As of today, NeuroSense Therapeutics has over 15 employees. |
| Who is the CEO of NeuroSense Therapeutics? | NeuroSense Therapeutics' CEO is Alon Ben-Noon. |
| Is NeuroSense Therapeutics publicly listed? | Yes, NeuroSense Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of NeuroSense Therapeutics? | NeuroSense Therapeutics trades under NRSN ticker. |
| When did NeuroSense Therapeutics go public? | NeuroSense Therapeutics went public in 2021. |
| Who are competitors of NeuroSense Therapeutics? | NeuroSense Therapeutics main competitors are Diamyd Medical, Tevogen Bio, Gensight Biologics, Skye Bioscience. |
| What is the current market cap of NeuroSense Therapeutics? | NeuroSense Therapeutics' current market cap is $24M. |
| What is the current revenue of NeuroSense Therapeutics? | NeuroSense Therapeutics' last 12 months revenue is $196K. |
| What is the current revenue growth of NeuroSense Therapeutics? | NeuroSense Therapeutics revenue growth (NTM/LTM) is 624%. |
| What is the current EV/Revenue multiple of NeuroSense Therapeutics? | Current revenue multiple of NeuroSense Therapeutics is 124.6x. |
| Is NeuroSense Therapeutics profitable? | No, NeuroSense Therapeutics is not profitable. |
| What is the current net income of NeuroSense Therapeutics? | NeuroSense Therapeutics' last 12 months net income is ($11M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.